Tone mix
Week by week 52 weeks
Share of Novartis AG's 888 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Aug 24, 2026 · tone -100Novartis India Ltd Slides 2.56%-141
- Week of Oct 5, 2026 · tone +81Health: Novartis strikes up to $7.8 billion mRNA deal with China's Abogen+92
- Week of Aug 10, 2026 · tone -27Swiss drug applications drop amid Trump's MFN policy (NVS:NYSE)-73
- Week of Oct 12, 2026 · tone +55Novartis FY2027 Earnings Forecast Cut by Erste Group Bank+66
- Week of Dec 29, 2025 · tone 0Destempasidis Calls Novartis 'OPEKEPE of Drugs'-61
- Week of Oct 26, 2026 · tone +52Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity+53
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Novartis AG in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 9 | -37 |
| Last 30 sessions | 63 | +40 |
| Last 90 sessions | 319 | +10 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, November 6, 2026
1 headline, average tone -24: 0 positive, 0 neutral and 1 negative. Showing all 1.
- www.techtimes.com · 1 outletNovartis Confirms Zolgensma Caused Tumors in Two Children Via Gene Therapy Vector IntegrationNegative
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Novartis Confirms Zolgensma Caused Tumors in Two Children Via Gene Therapy Vector Integration | www.techtimes.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, November 5, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- 247wallst.com · 1 outletNovartis at $165: What a Fresh 52-Week High Means NowPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Novartis at $165: What a Fresh 52-Week High Means Now | 247wallst.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, November 4, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.fool.com · 1 outletNovartis: 3 Key Takeaways for Long-Term InvestorsNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Novartis: 3 Key Takeaways for Long-Term Investors | www.fool.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, November 3, 2026
4 headlines, average tone -98: 0 positive, 0 neutral and 4 negative. Showing all 4.
- www.prnewswire.com · 2 outletsBioArctic collaborator Novartis terminates agreementNegative
- en.shafaqna.com · 1 outletnovartis heart drug lp(a) trial failure raises heart health questionsNegative
- www.medscape.com · 1 outletNovartis Heart Drug Failure Leaves Doctors Seeking Evidence for Genetic Cholesterol TargetNegative
- econotimes.com · 1 outletBioArctic Says Novartis Ends Deal With Up to US$772 Million in Potential MilestonesNegative
Show the table · 4 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| BioArctic collaborator Novartis terminates agreement | www.prnewswire.com | 2 | Negative |
| novartis heart drug lp(a) trial failure raises heart health questions | en.shafaqna.com | 1 | Negative |
| Novartis Heart Drug Failure Leaves Doctors Seeking Evidence for Genetic Cholesterol Target | www.medscape.com | 1 | Negative |
| BioArctic Says Novartis Ends Deal With Up to US$772 Million in Potential Milestones | econotimes.com | 1 | Negative |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
1 headline, average tone +72: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.biopharmadive.com · 1 outletEarnings roundup: Lilly's unwavering momentum, Novartis' rebound and GSK's waiting gamePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Earnings roundup: Lilly's unwavering momentum, Novartis' rebound and GSK's waiting game | www.biopharmadive.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Novartis AG, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.